Corporate Banner
Satellite Banner
Biomolecular Screening
Scientific Community
Become a Member | Sign in
Home>News>This Article

European Research Project Aims at Early Diagnosis of Memory Disorders

Published: Thursday, March 20, 2014
Last Updated: Thursday, March 20, 2014
Bookmark and Share
800 patients to participate in testing new diagnostic procedures.

The PredictND project, started by European research organizations, aims at developing and validating new procedures for the earlier diagnosis of memory disorders and for detecting individuals at high risk of developing memory disorders.

Millions of Europeans who are at risk for experiencing any kind of memory loss would benefit from such a solution. The novel approach will be tested on 800 patients in four hospitals in Finland, Denmark, the Netherlands and Italy. The PredictND project is coordinated by VTT Technical Research Centre of Finland and funded by the EU.

Diagnostics of memory disorders is complicated, as multiple reasons can explain the degeneration of cognitive capacity. Alzheimer’s disease is the most common reason explaining 60-70% of cases. Today no single test or biomarker can predict whether a particular person will develop Alzheimer´s disease.

On top of that, clinicians experience an overload of information: they need to combine information from multiple tests and biomarkers in order to find the correct reason and name for the disease.

The PredictND research project, co-funded under the European 7thFramework Programme, will not only develop new, cost-efficient methods for enabling earlier and more reliable diagnostics of different memory disorders in clinical practice; PredictND will also provide computer-based tools that help clinicians form a holistic view of the patient by combining information from several sources, such as clinical tests, imaging and blood samples, and by comparing these measurements to previously diagnosed cases available in hospital databases.

"Alongside the better prediction of memory disorders, PredictND wants to provide a completely new approach for clinicians to systematically manage the information load that they are facing in current clinical practice", says Dr Jyrki Lötjönen, Scientific Coordinator of PredictND, VTT. "For that, we intend to transfer state-of-the-art computer-based technologies, for example for image analysis and machine learning, to a modern hospital environment in order to assist clinicians in their daily work. At the earliest, the new diagnostics tool could enter the market in a couple of years.”

The novel approach will be tested on 800 patients in four top hospitals in Europe: Kuopio (Finland), Copenhagen (Denmark), Amsterdam (the Netherlands) and Perugia (Italy), and compared with the existing diagnostic procedures.

Early detection is crucial
"This project has been granted European funding because increasing the quality of life in Europe is high on our agenda, and memory disorders affect this seriously", explains Project Officer Amalia Vlad of the European Commission. "To treat these disorders, early detection and an accurate diagnosis are essential."

It is important to predict memory disorders before the symptoms start, especially in Alzheimer's disease where the pathological process leads to the death of brain cells. New cost-efficient methods are needed for detecting persons at high risk and corroborating this with new ways of intervention. PredictND will develop novel cost-efficient biomarkers for the early detection of persons at high risk.

One of the project partners, GE Healthcare, has already developed a PET amyloid imaging agent, a potentially powerful tool in aiding the diagnosis of Alzheimer's disease. "But results from this tool must be combined with other types of information to fully characterize the patient", says Dr Lennart Thurfjell, Head of Biomarkers and Software, Medical Diagnostics at GE Healthcare.

Big data
The use of modern machine learning techniques and the exploitation of large databases, i.e., "big data" as it is called nowadays, is still relatively limited in clinical practice. Hilkka Soininen, professor of neurology at the University of Eastern Finland, says: "The innovation of the project is to test the decision-making tool for the detection and differentiation of memory diseases at earliest phases. Detecting signs of progressive memory disease in time will allow earlier interventions and treatments. Tools which support decision-making will be common into tomorrow’s clinical practice. These tools can help a clinician to extract the most important information and profiles among the multitude of data.”

Dementia is a health priority in Europe. Alzheimer's disease alone accounts for costs equivalent to about 1% of the gross domestic product (GDP) of the whole world and the number of persons affected will double in the next 20 years. Alzheimer's disease affects more than five million people in Europe.

The PredictND research consortium is formed of eight top-level research, academic, industrial and medical organizations from five different European countries: VTT Technical Research Centre of Finland, GE Healthcare (UK), Imperial College London (UK), the University of Eastern Finland, Rigshospitalet (Denmark), VU Medical Center Amsterdam (the Netherlands), the University of Perugia (Italy) and Alzheimer Europe (Luxembourg).

The project will run for four years with a total budget of €4,219,646, to which the EU will contribute €3,148,000.

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,600+ scientific posters on ePosters
  • More than 3,800+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Novel Cancer Cell DNA Damage Repair Mechanism
Findings result from application of the cell microarray screening method developed at VTT.
Monday, December 23, 2013
VTT and GE Healthcare Developing Novel Biomarkers to Predict Alzheimer’s Disease
VTT and University of Eastern Finland scientists have discovered a serum biochemical signature.
Wednesday, June 27, 2012
Scientific News
Promising Drug Candidate to Treat Chronic Itch
In a new study, scientists from the Florida campus of The Scripps Research Institute (TSRI) describe a class of compounds with the potential to stop chronic itch without the adverse side effects normally associated with medicating the condition.
Are Changes to Current Colorectal Cancer Screening Guidelines Required?
Editorial suggests more research is needed to pinpoint age to end aggressive screening.
Assessing Cancer Patient Survival and Drug Sensitivity
RNA editing events another way to investigate biomarkers and therapy targets.
New Molecular Marker for Killer Cells
Cell marker enables prognosis about the course of infections.
Potential Target for Treatment of Autism
Grant of $2.4 million will support further research.
Sniffing Out Cancer
Scientists have been exploring new ways to “smell” signs of cancer by analyzing what’s in patients’ breath.
Inroads Against Leukaemia
Potential for halting disease in molecule isolated from sea sponges.
Molecular ‘Kiss Of Death’ Flags Pathogens For Destruction
Researchers have discovered that our bodies mark pathogen-containing vacuoles for destruction by using a molecule called ubiquitin, commonly known as the "kiss of death."
A New Single-Molecule Tool to Observe Enzymes at Work
A team of scientists at the University of Washington and the biotechnology company Illumina have created an innovative tool to directly detect the delicate, single-molecule interactions between DNA and enzymatic proteins.
Milestone Single-Biomolecule Imaging Technique May Advance Drug Design
The first nanometer resolved image of individual tobacco mosaic virions shows the potential of low-energy electron holography for imaging biomolecules at a single particle level; a milestone in structural biology and a potential new tool for drug design.

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,600+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,800+ scientific videos